Health Condition 1: D631- Anemia in chronic kidney disease
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Dr Reddys Laboratories Road No Banjara Hills Hyderabad Telangana India
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female subjects, aged �18 years. 2. CKD patients (as defined in KDIGO guidelines) with Hb level less than 10g/dl (as per the latest available test report), with/without the need of dialysis and who have newly commenced therapy for anemia, including at least one agent each for stimulating erythropoiesis and iron supplementation, with or without any other agents. 3. Willing to provide inform consent to share the data.
Exclusion criteria
Exclusion criteria: Patients with presence of uncontrolled hypertension, uncontrolled hyperparathyroidism or hypothyroidism or bleeding disorders or acute illness or chronic blood loss or hemoglobinopathy, or malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Clinical characteristics in terms of demographics and medical condition of CKD 2. Utilization patterns of various pharmacological classes including but not limited to agents administered to stimulate erythropoiesis, iron supplementation used in management of anaemia in CKD. 3. Assessment of response to various treatment approaches in terms of haematological parameters and quality of life (QoL) based on KDQOL (KDQOL-SFââ??¢ v1.3) 4. Analysis of observed side effects during the management of anaemia in CKD patients with anaemia.Timepoint: Baseline, 3 months, 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Sagar Katare
Dr. Reddys Laboratories Ltd
Outcome results
None listed